目的 分析不同的CYP2C9和VKORC1分型患者胺碘酮对华法林的抗凝作用的影响。 方法 纳入从2010年1月至2012年11月某三甲医院应用华法林的入院患者，收集患者一般信息、合并用药及其他临床相关数据，检测患者VKORCl和CYP2C9基因型; 比较使用或未使用胺碘酮治疗患者抗凝稳定期INR值及华法林用量，纳入基因分型进行华法林/胺碘酮相互作用的亚组分析。 结果 未发现胺碘酮应用患者华法林稳定期用量和INR值的统计学差义，基因型亚组差异无统计学意义。 结论 院内短期合并使用胺碘酮患者对华法林稳定剂量和INR值未见显著影响。
Abstract
OBJECTIVE To analyse the effect of amiodarone on the warfarin anticoagulation effects in different CYP2C9 and VORCORC1 status. METHODS From January 2010 to November 2012, patients on warfarin therapy with or without amiodarone medication were included whose blood samples were collected and tested in VKORCl and CYP2C9 genotypes and whose clinical data were collected. The clinical characterics, warfarin medication related data were compared between the groups with and without amiodarone therapy and the genotype status were used in the following subgroup analysis.RESULTS There are no statistically difference of warfarin dosage or INR(international ratio of PT) value between the groups with and without amiodarone medication and no statistically difference in the following analysis of genotype subgroup. CONCLUSION The patients on short-duration usage of amiodarone has no obviously effect on warfarin stable dosage and INR value during stable dosage.
关键词
华法林 /
胺碘酮 /
药物相互作用 /
基因分析 /
VKORC1 /
CYP2C9
{{custom_keyword}} /
Key words
warfarin /
amiodarone /
drug interaction /
gene analysis /
VKORC1 /
CYP2C9
{{custom_keyword}} /
中图分类号：
R969.2
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ZHANG X Y, WANG J C, WEI X,et al. Analysis of elderly non-valvular atrial fibrillation and antithrombotic treatment. Chin J Geriatric Dis(中华老年多器官疾病杂志),2009,(6),529-532.[2] HIGASHIM K,VEENSTRAD L,KONDOL M,et al.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA,2002,287(13):1690-1698.[3] ZHANG YT,LIANG X,ZHAO N,et al. Effect of Polymorphism in VKORC1 and CYP2C9 on Warfarin Dosage in Elderly Patients . Chin Pharm J (中国药学杂志),2012,47(23):1930-1933.[4] ZHANG Y T, LIANG X, HU X,et al.Rapid detection of warfarin-related gene of VKORC1 polymorphisms of CYP2C9 based on the ligase reaction . Chin J Clin Pharm Ther(中国临床药理学与治疗学),2010,15(12): 1395-1401.[5] MARTINOWITZ U, RABINOVICH J, GOLDFARB D, et al. Interaction between warfarin sodium and amiodarone. N Engl J Med, 1981,304 (11): 671-672.[6] KERIN N Z, BLEVINS R D, GOLDMAN L,et al. The incidence, magnitude, and timecourse of the amiodarone-warfarin interaction.Arch Intern Med, 1988, 148(8):1779-81.[7] HEIMARK L D, WIENKERS L, KUNZE K, et al.The mechanism of the interaction between amiodarone and warfarin in humans.Clin Pharmacol Ther, 1992,51(4):398-407.[8] XIE S, LIU H, LOU Y, et al. Effects of Amiodarone Dose on the Initial Anticoagulation Response of Warfarin Within 1 Week in Patients with Heart Valve Replacement. Chin Pharm J (中国药学杂志),2010,45(8):593-596.[9] NAGANUMA M,SHIGA T,NISHIKATA K,et al.Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy.J Cardiovasc Pharmacol Ther,2001,6(4):363-367. YUAN H, CHEN J J, LEE M T,et al.Anoval functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Hum Mol Gene,2005,14(134):1745-1751.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(632 KB)
